fulvestrant

Action and Spectrum

Drug Interaction

Adverse Reaction

Frequency defined: 

>10%: 

Decreased serum glucose 

Hot flash 

Abdominal pain 

Constipation 

Decreased appetite 

Nausea 

Stomatitis 

Vomiting 

Anemia 

Lymphocytopenia 

Infection 

Fatigue 

Arthralgia 

Dyspnea  

1%-10% 

Alopecia 

Peripheral edema 

Skin rash 

Anorexia 

Decreased serum albumin and phosphate 

Weight loss 

Leukopenia 

Dizziness 

Asthenia 

Muscle pain 

Frequency not defined: 

Neuralgia 

Peripheral neuropathy 

Sciatica 

Hepatic failure 

Black Box Warning

Contraindication / Caution

Pregnancy / Lactation

Pregnancy consideration: based on animal studies, it may cause harm to patients who can become pregnant. 

Lactation: excretion of fulvestrant in breast milk is not known.  

Pregnancy category: 

• Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester. 
• Category B: There is no evidence of risk to the fetus found in animal reproduction studies and there are not enough studies on pregnant women. 
• Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women 
• Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits. 
• Category X: Drugs listed in this category outweigh risks over benefits These category drugs should be prohibited for pregnant women. 
• Category N: There is no data available for the drug under this category. 

Pharmacology

Adminstartion

Patient Information Leaflet

Patient information leaflet 

Generic Name: Fulvestrant 

Pronounced: fov-stant 

Why do we use fulvestrant? 

Fulvestrant is an estrogen receptor antagonist class of antineoplastic drug. It is used to treat breast cancer.